Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 116Carcinoma, Non-Small-Cell Lung 101Carcinoma, Renal Cell 67Colorectal Neoplasms 46Neoplasm Metastasis 40Squamous Cell Carcinoma of Head and Neck 38Carcinoma, Hepatocellular 38Neoplasms 35Lung Neoplasms 34Stomach Neoplasms 33Urinary Bladder Neoplasms 22Hodgkin Disease 20Carcinoma, Transitional Cell 20Brain Neoplasms 20Pancreatic Neoplasms 18Ovarian Neoplasms 18Prostatic Neoplasms 16Head and Neck Neoplasms 16Colonic Neoplasms 16Skin Neoplasms 15Sarcoma 14Glioblastoma 14Adenocarcinoma Of Esophagus 14Triple Negative Breast Neoplasms 13Carcinoma, Merkel Cell 13Small Cell Lung Carcinoma 12Rectal Neoplasms 12Esophageal Neoplasms 12Breast Neoplasms 12Uveal Melanoma 11

Interventions

pembrolizumab 6Cetuximab 5olaparib 3atezolizumab 3Injections 3fludarabine 2Trastuzumab 2Docetaxel 2Cyclophosphamide 2Bevacizumab 2zimberelimab 1zansecimab 1tocilizumab 1taxane 1spartalizumab 1somatostatin receptor 2 1ribociclib 1pralsetinib 1pertuzumab 1pegylated granulocyte colony-stimulating factor 1lenvatinib 1ipatasertib 1inavolisib 1fludarabine phosphate 1entrectinib 1encorafenib 1durvalumab 1dapagliflozin 1cemiplimab 1brigimadlin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × Nivolumab × 1 year × Clear all
NCT07176975 2026-05-26

A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

Boehringer Ingelheim

Phase 1 Not yet recruiting
46 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡